Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mannkind Corp (NQ: MNKD ) 5.710 -0.010 (-0.17%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,685,541 Open 5.720 Bid (Size) 5.620 (5) Ask (Size) 5.770 (2) Prev. Close 5.720 Today's Range 5.640 - 5.770 52wk Range 3.170 - 6.040 Shares Outstanding 264,305,532 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News "Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker June 27, 2024 Our first-ever twin bill. Via The Motley Fool INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions June 22, 2024 From MannKind Via GlobeNewswire Performance YTD +45.66% +45.66% 1 Month +17.49% +17.49% 3 Month +36.60% +36.60% 6 Month +69.94% +69.94% 1 Year +30.07% +30.07% More News Read More Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions June 05, 2024 From MannKind Via GlobeNewswire Earnings Scheduled For February 27, 2024 February 27, 2024 Via Benzinga MannKind Earnings Preview February 26, 2024 Via Benzinga MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix May 29, 2024 From MannKind Via GlobeNewswire MannKind (MNKD) Q1 2024 Earnings Call Transcript May 09, 2024 Via The Motley Fool Topics Earnings Exposures Financial MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024 May 08, 2024 Via InvestorPlace MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update May 08, 2024 From MannKind Via GlobeNewswire MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease May 06, 2024 From MannKind Via GlobeNewswire MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 May 01, 2024 From MannKind Via GlobeNewswire MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases April 30, 2024 From MannKind Via GlobeNewswire MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease April 29, 2024 From MannKind Via GlobeNewswire MannKind Repays Certain Debt Obligations April 03, 2024 From MannKind Via GlobeNewswire MannKind Announces CFO Transition March 26, 2024 From MannKind Via GlobeNewswire Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 11, 2024 Via Benzinga Exposures Product Safety EQT, Genie Energy And Other Big Stocks Moving Lower On Monday March 11, 2024 Via Benzinga Topics Stocks Exposures US Equities What's Going On With MannKind Stock? March 11, 2024 Via Benzinga INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps March 11, 2024 From MannKind Via GlobeNewswire Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out' March 08, 2024 Via Benzinga MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 March 05, 2024 From MannKind Via GlobeNewswire MannKind Corporation Announces Participation at Upcoming Conferences March 04, 2024 From MannKind Via GlobeNewswire MannKind (MNKD) Q4 2023 Earnings Call Transcript February 28, 2024 Via The Motley Fool Topics Earnings Exposures Financial MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update February 27, 2024 From MannKind Via GlobeNewswire MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 February 20, 2024 From MannKind Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.